Supernus Pharmaceuticals ... (SUPN)
NASDAQ: SUPN
· Real-Time Price · USD
32.28
0.00 (0.00%)
At close: Jun 23, 2025, 3:06 PM
Supernus Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| APOKYN Revenue | 73.93M | 75.08M | 75.31M | 99.23M | 74.3M | 88.19M | 84.58M |
| APOKYN Revenue Growth | -1.54% | -0.29% | -24.11% | +33.56% | -15.75% | +4.27% | n/a |
| GOCOVRI Revenue | 130.82M | 119.64M | 104.42M | 9.78M | 98.72M | 383.4M | 399.87M |
| GOCOVRI Revenue Growth | +9.35% | +14.57% | +967.92% | -90.10% | -74.25% | -4.12% | n/a |
| Manufactured Product, Other Revenue | 29.01M | 31.28M | 31.82M | 110.71M | 509.35M | 295.21M | n/a |
| Manufactured Product, Other Revenue Growth | -7.27% | -1.69% | -71.26% | -78.26% | +72.54% | n/a | n/a |
| Oxtellar X R Revenue | 99.46M | 113.4M | 115.34M | 567.5M | 319.64M | n/a | n/a |
| Oxtellar X R Revenue Growth | -12.29% | -1.68% | -79.68% | +77.54% | n/a | n/a | n/a |
| Product Revenue | 637.7M | 573.93M | 649.43M | 9.88M | n/a | n/a | n/a |
| Product Revenue Growth | +11.11% | -11.63% | +6473.86% | n/a | n/a | n/a | n/a |
| Qelbree Revenue | 241.27M | 140.19M | 61.32M | 304.82M | n/a | n/a | n/a |
| Qelbree Revenue Growth | +72.10% | +128.62% | -79.88% | n/a | n/a | n/a | n/a |
| Royalty, License And Other Revenue Revenue | 24.12M | 94.34M | 261.22M | n/a | n/a | n/a | n/a |
| Royalty, License And Other Revenue Revenue Growth | -74.43% | -63.89% | n/a | n/a | n/a | n/a | n/a |
| Trokendi Xr Revenue | 63.2M | n/a | n/a | n/a | n/a | n/a | n/a |
| Trokendi Xr Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 89.94M | 79.41M | 69.75M | 85.9M | 86.52M | 81.28M | 82.7M | 86.78M | 85.6M | 73.97M | 112.31M | 100.48M | 90.46M | 101.73M | 72.03M | 69.53M | 61.46M | 56.5M | 54.66M | 48.1M | 42.88M | 35.73M | 40.65M | 41.08M | 40.97M | 42.05M | 40.89M | 40.1M | 36.85M | 33.76M | 40.83M | 35.08M | 28.24M | 29.05M | 25.68M | 26.12M | 25.16M | 23.57M | 22.9M | 23.34M | 19.4M |
| Selling, General, and Administrative Revenue Growth | +13.27% | +13.84% | -18.80% | -0.71% | +6.44% | -1.71% | -4.70% | +1.38% | +15.72% | -34.14% | +11.78% | +11.07% | -11.08% | +41.24% | +3.59% | +13.14% | +8.77% | +3.37% | +13.63% | +12.19% | +20.01% | -12.11% | -1.06% | +0.28% | -2.57% | +2.83% | +1.98% | +8.81% | +9.14% | -17.30% | +16.38% | +24.22% | -2.81% | +13.16% | -1.71% | +3.82% | +6.76% | +2.91% | -1.87% | +20.28% | n/a |
| Research and Development Revenue | 26.93M | 28.05M | 29.04M | 25.58M | 24.32M | 22.74M | 22.66M | 24.38M | 21.21M | 17.77M | 19.55M | 16.39M | 20.84M | 21.08M | 19.65M | 15.46M | 34.28M | 17.94M | 16.84M | 22.25M | 18.94M | 19.79M | 16.94M | 16.97M | 15.39M | 29.84M | 20.42M | 20.04M | 18.91M | 16.17M | 12.98M | 10.82M | 9.6M | 13.25M | 7.87M | 11.11M | 10.56M | 9.45M | 9.13M | 6.88M | 3.68M |
| Research and Development Revenue Growth | -3.99% | -3.41% | +13.50% | +5.20% | +6.94% | +0.38% | -7.07% | +14.93% | +19.34% | -9.10% | +19.34% | -21.37% | -1.13% | +7.25% | +27.17% | -54.92% | +91.10% | +6.53% | -24.31% | +17.48% | -4.32% | +16.82% | -0.16% | +10.24% | -48.41% | +46.12% | +1.92% | +5.98% | +16.91% | +24.60% | +19.93% | +12.73% | -27.55% | +68.43% | -29.17% | +5.18% | +11.81% | +3.47% | +32.73% | +86.75% | n/a |
| Sales and Marketing Revenue | 63.28M | 54.59M | 54.33M | 58.8M | 59.57M | 55.28M | 56.78M | 59.89M | 57.23M | 47.99M | 85.7M | 73.58M | 60.51M | 62.18M | 50.7M | 48.38M | 38.45M | 36.59M | 39.17M | 29.95M | 29.04M | 8.3M | 29.58M | 30.22M | 30.75M | 12.8M | 11.6M | 11.1M | 7.9M | 7.7M | 9.6M | 9.8M | 6.7M | 5.7M | 4.9M | 5M | 6.4M | 19.3M | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | +15.91% | +0.49% | -7.61% | -1.28% | +7.76% | -2.66% | -5.19% | +4.65% | +19.25% | -44.00% | +16.48% | +21.60% | -2.68% | +22.63% | +4.80% | +25.84% | +5.07% | -6.59% | +30.79% | +3.13% | +249.89% | -71.94% | -2.10% | -1.72% | +140.23% | +10.34% | +4.50% | +40.51% | +2.60% | -19.79% | -2.04% | +46.27% | +17.54% | +16.33% | -2.00% | -21.88% | -66.84% | n/a | n/a | n/a | n/a |